Venus Concept Inc. is a medical aesthetic technology company based in Toronto, Canada, that develops and commercializes minimally invasive and non-invasive devices for aesthetic and hair restoration procedures. Its product portfolio includes a range of advanced systems, such as Venus Versa, a multi-treatment platform designed for various aesthetic procedures; Venus Legacy, which addresses challenging facial and body aesthetic concerns; and Venus Fiore, focused on internal vaginal health restoration. Additionally, the company offers Venus Viva for customizable skin resurfacing, Venus Freeze Plus for non-invasive skin tightening, and Venus Bliss for fat reduction. For hair restoration, Venus Concept provides NeoGraft, an automated system for follicle harvesting, along with ARTAS and ARTAS iX robotic systems. The company primarily generates its revenue from the United States, driven by a team of experienced executives and researchers dedicated to enhancing the medical aesthetics industry.
Venus Concept Inc. is a medical aesthetic technology company based in Toronto, Canada, that develops and commercializes minimally invasive and non-invasive devices for aesthetic and hair restoration procedures. Its product portfolio includes a range of advanced systems, such as Venus Versa, a multi-treatment platform designed for various aesthetic procedures; Venus Legacy, which addresses challenging facial and body aesthetic concerns; and Venus Fiore, focused on internal vaginal health restoration. Additionally, the company offers Venus Viva for customizable skin resurfacing, Venus Freeze Plus for non-invasive skin tightening, and Venus Bliss for fat reduction. For hair restoration, Venus Concept provides NeoGraft, an automated system for follicle harvesting, along with ARTAS and ARTAS iX robotic systems. The company primarily generates its revenue from the United States, driven by a team of experienced executives and researchers dedicated to enhancing the medical aesthetics industry.
Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.
Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.
Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.
Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.
Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.
Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.
Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.
Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.
Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.
Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.
Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.
Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.
Calibrate is a digital health company focused on improving metabolic health to achieve sustainable weight loss. Founded in 2020 and based in New York, Calibrate offers a virtual weight management program that integrates FDA-approved metabolic medications with personalized coaching and a comprehensive curriculum designed by experts in obesity and nutrition. The platform emphasizes behavior change and provides one-on-one virtual sessions with healthcare professionals, aiming to foster lasting habits for its users. Calibrate's approach combines telemedicine with a value-based pricing model, ensuring effective obesity treatment outcomes while facilitating the necessary physiological changes for improved health.
Monteris Medical, Inc. is a medical device company that specializes in developing and marketing technologies for minimally invasive neurosurgery, particularly focused on the treatment of brain lesions. The company's flagship product, the NeuroBlate System, is a laser thermotherapy system designed for the volumetric ablation of pathological brain lesions, including both primary and metastatic tumors. This system utilizes magnetic resonance imaging (MRI) guidance and applies focused laser energy to effectively target and ablate tumors while minimizing damage to surrounding healthy tissue. Monteris Medical also offers various stereotactic anchoring devices for precise image-guided trajectory alignment, as well as stabilization systems for MRI-based procedures that require head fixation. Founded in 1999 and headquartered in Plymouth, Minnesota, the company serves neurosurgeons across the United States through a dedicated sales force. Monteris Medical was previously known as AutoLITT until rebranding in 2003.
Willow, founded in 2014 and based in Mountain View, California, is a company that specializes in the development and manufacturing of wearable breast pumps and related breastfeeding products. The company offers a range of items including in-bra breast pumps, milk bags, replacement parts, pumping bras, and accessories like flanges and chargers. Willow's breast pumps are designed to be mobile and hands-free, allowing mothers to pump discreetly and conveniently. The devices are cordless, spill-proof, and equipped with a mobile application that tracks milk output, facilitating a hassle-free pumping experience for mothers on the go.
Alto Pharmacy is a leading digital pharmacy established in 2015 that aims to transform the pharmacy industry by providing a more efficient and accessible experience for patients. The company emphasizes the importance of pharmacists in the healthcare journey, integrating expert care with innovative technology. This approach allows Alto to offer medication management, scheduled delivery, and easy communication through its mobile app and web portal. With over three million prescriptions fulfilled and operations in twelve markets, Alto is committed to enhancing patient care and convenience. Its focus on customer satisfaction is reflected in its high Net Promoter Score, indicating a strong preference among users for its services.
Bigfoot Biomedical, Inc. is a healthcare company focused on improving diabetes management for individuals with Type 1 Diabetes. Established in 2014 and based in Milpitas, California, the company develops an advanced diabetes management system that integrates automated insulin delivery with cloud connectivity and user-friendly automation. This system aims to optimize insulin dosing and delivery through a cohesive ecosystem of medical devices, including an automated infusion pump and a connected insulin pen. Leveraging machine learning and secure consumer technologies, Bigfoot Biomedical provides a comprehensive digital platform that addresses the cognitive, emotional, and financial challenges associated with diabetes management. The company's innovative approach includes a first-of-its-kind monthly subscription service model, making diabetes care more accessible and efficient for patients.
Private Equity Round in 2021
Dialyze Direct is a healthcare company provides staff assisted home hemodialysis services to elderly patients with End Stage Renal Disease.
SomaLogic, Inc. is a commercial-stage company based in Boulder, Colorado, specializing in protein biomarker discovery and clinical diagnostics. The company utilizes its proprietary technology platform, SomaScan, which allows for the measurement of proteins with a precision comparable to DNA measurement. This technology enhances the understanding of the molecular bases of health and disease, surpassing traditional genomic methods. SomaLogic develops and offers SOMAmers, modified nucleic acid-based protein-binding reagents, and provides diagnostic tests and protein measurement solutions for various diseases, including those in oncology, neurology, and cardiovascular health. Their products serve multiple applications, including life sciences research, therapeutic drug development, and clinical diagnostics, making significant contributions to the fields of biological and medical sciences. Founded in 1999, SomaLogic continues to advance the capabilities of proteomics in both research and clinical settings.
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company dedicated to developing and commercializing innovative products that address unmet medical needs both in the United States and internationally. The company's commercial portfolio features several oral soluble film formulations, including Sympazan for Lennox-Gastaut syndrome, Suboxone for opioid dependence, Exservan for Amyotrophic Lateral Sclerosis, and Zuplenz for chemotherapy-induced nausea and vomiting. Its pipeline includes advanced candidates such as Libervant, a buccal film for epileptic seizures, and various sublingual films aimed at treating conditions like anaphylaxis and Parkinson’s disease. Founded in 2004 and headquartered in Warren, New Jersey, Aquestive Therapeutics emphasizes its commitment to addressing critical healthcare challenges, particularly in Central Nervous System disorders, while also collaborating with pharmaceutical partners to enhance its product offerings.
Veran Medical Technologies is a medical device company focused on developing minimally invasive solutions for interventional oncology procedures. Based in St. Louis, Missouri, the company offers a range of products, including the SPiNView thoracic navigation system, which aids physicians in performing biopsies on solitary pulmonary nodules for early lung cancer diagnosis. Other key offerings include the ig4 IR System, a platform that assists in biopsies and ablations for various organs, and the SPiNPerc device for hybrid diagnostic procedures. The company also provides vPad2, a tracking device for instrument positioning during surgery, and the vTrack 2.0 Instruments, which guide physicians to peripheral lung regions. Veran's technology enhances diagnostic accuracy and therapy delivery by integrating various imaging modalities, ultimately aiming to improve patient outcomes through earlier cancer detection and treatment.
Private Equity Round in 2018
SomaLogic, Inc. is a commercial-stage company based in Boulder, Colorado, specializing in protein biomarker discovery and clinical diagnostics. The company utilizes its proprietary technology platform, SomaScan, which allows for the measurement of proteins with a precision comparable to DNA measurement. This technology enhances the understanding of the molecular bases of health and disease, surpassing traditional genomic methods. SomaLogic develops and offers SOMAmers, modified nucleic acid-based protein-binding reagents, and provides diagnostic tests and protein measurement solutions for various diseases, including those in oncology, neurology, and cardiovascular health. Their products serve multiple applications, including life sciences research, therapeutic drug development, and clinical diagnostics, making significant contributions to the fields of biological and medical sciences. Founded in 1999, SomaLogic continues to advance the capabilities of proteomics in both research and clinical settings.
Establishment Labs S.A. is a medical technology company based in Alajuela, Costa Rica, that specializes in the design, development, manufacturing, and marketing of silicone-filled breast and body shaping implants. The company's flagship product line, Motiva Implants, features a variety of options in surface, shape, size, base, and projection and is sold in over 60 countries. Establishment Labs also offers innovative solutions such as the MotivaImagine application, which aids in surgical planning, and Q Inside Safety Technology, a radio frequency identification transponder that provides surgeons with implant-specific data. Additionally, the company provides Puregraft technology for purified fat reinjection and operates a center for breast augmentation consultations. Its manufacturing facilities comply with FDA and ISO standards, and the company has regulatory offices in the United States and a distribution center in Belgium. Established in 2004, Establishment Labs serves plastic surgeons and patients globally, emphasizing innovation in its product offerings.
BioQ Pharma is a late stage specialty pharmaceutical company focused on developing and commercializing a portfolio of large volume ready-to-use infusible pharmaceuticals. Our vision is to set a new standard of care in the presentation and administration of infusible pharmaceuticals via our proprietary unit-dose infusion systems that can be deployed quickly and conveniently at the point of care with one touch. Our infusion platform is intended to address some of the most pressing unmet needs in infusion today: cost, medication error, sterility, efficiency, and patient quality of life.
BioQ Pharma is a late stage specialty pharmaceutical company focused on developing and commercializing a portfolio of large volume ready-to-use infusible pharmaceuticals. Our vision is to set a new standard of care in the presentation and administration of infusible pharmaceuticals via our proprietary unit-dose infusion systems that can be deployed quickly and conveniently at the point of care with one touch. Our infusion platform is intended to address some of the most pressing unmet needs in infusion today: cost, medication error, sterility, efficiency, and patient quality of life.
Venus Concept Inc. is a medical aesthetic technology company based in Toronto, Canada, that develops and commercializes minimally invasive and non-invasive devices for aesthetic and hair restoration procedures. Its product portfolio includes a range of advanced systems, such as Venus Versa, a multi-treatment platform designed for various aesthetic procedures; Venus Legacy, which addresses challenging facial and body aesthetic concerns; and Venus Fiore, focused on internal vaginal health restoration. Additionally, the company offers Venus Viva for customizable skin resurfacing, Venus Freeze Plus for non-invasive skin tightening, and Venus Bliss for fat reduction. For hair restoration, Venus Concept provides NeoGraft, an automated system for follicle harvesting, along with ARTAS and ARTAS iX robotic systems. The company primarily generates its revenue from the United States, driven by a team of experienced executives and researchers dedicated to enhancing the medical aesthetics industry.